-
公开(公告)号：US20040259923A1
公开(公告)日：2004-12-23
申请号：US10764529
申请日：2004-01-27
发明人： Takayuki Inoue , Takashi Tojo , Masataka Morita , Mitsuru Ohkubo , Kousei Yoshihara , Akira Nagashima
IPC分类号： A61K031/427 , A61K031/426 , C07D417/02
CPC分类号： C07D417/06 , C07D277/46 , C07D277/48 , C07D277/56 , C07D417/12
摘要： A compound of the formula (I): R1nullNHnullXnullY-Z (I) wherein each symbol is as defined in the specification, or a pharmaceutically acceptable salt thereof useful as a vascular adhesion protein-1 (VAP-1) inhibitor, a pharmaceutical composition, a method for preventing or treating a VAP-1 associated disease, especially macular edema, which method includes administering an effective amount of the compound or a pharmaceutically acceptable salt thereof to a mammal, and the like.
摘要翻译： 式（I）的化合物：其中各符号如说明书中所定义，或其药学上可接受的盐可用作血管粘附蛋白-1（VAP-1）抑制剂的R 1 -NH-XYZ（I） ，药物组合物，预防或治疗VAP-1相关疾病，尤其是黄斑水肿的方法，该方法包括向哺乳动物施用有效量的化合物或其药学上可接受的盐等。
-
公开(公告)号：US20040162250A1
公开(公告)日：2004-08-19
申请号：US10366718
申请日：2003-02-14
发明人： Ryuichi Morishita , Toshio Ogiwara , Toshiko Sugimoto , Kazuhiro Maeda , Ikuo Kawamura , Toshiyuki Chiba
IPC分类号： A61K048/00 , A61K038/17
CPC分类号： A61K31/00 , A61K38/00 , A61K48/005 , C12N15/113 , C12N2310/13 , C12N2310/315
摘要： Administration of a decoy, i.e. a compound which specifically antagonizes the nucleic acid domain to which NF-nullB is bound, is effective in the treatment and prevention of diseases caused by the transcriptional regulatory factor NF-nullB, such as ischemic diseases, inflammatory diseases, autoimmune diseases, cancer metastasis and invasion, and cachexia.
摘要翻译： 施用诱饵，即特异性拮抗NF-κB结合的核酸结构域的化合物在治疗和预防由转录调节因子NF-κB引起的疾病中是有效的，例如缺血性疾病，炎性疾病， 自身免疫性疾病，癌症转移和侵袭以及恶病质。
-
公开(公告)号：US20040157769A1
公开(公告)日：2004-08-12
申请号：US10772281
申请日：2004-02-06
发明人： Seiji Sawai , Akihiro Kasai , Kazumi Ohtomo
IPC分类号： A61K038/12
摘要： A stabilized pharmaceutical composition in lyophilized form comprising: a cyclic polypeptide compound represented by the general formula (I): 1 wherein R1 is a hydrogen atom or an acyl group and R2 and R3 are, the same or different, a hydrogen atom or a hydroxyl group, or a salt thereof and the stabilizer.
摘要翻译： 一种冻干形式的稳定化药物组合物，其包含：由通式（I）表示的环状多肽化合物：其中R 1为氢原子或酰基，R 2和R 3为相同或 不同的氢原子或羟基，或其盐和稳定剂。
-
4.发明申请Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same 审中-公开三环化合物，其生产方法和含有它们的药物组合物公开(公告)号：US20040029908A1
公开(公告)日：2004-02-12
申请号：US10426659
申请日：2003-05-01
发明人： Masakuni Okuhara , Hirokazu Tanaka , Toshio Goto , Tohru Kino , Hiroshi Hatanaka
IPC分类号： A61K031/4745 , C07D491/14
CPC分类号： C07D498/18 , C07H19/01 , C12P17/188 , C12P19/44 , C12R1/465 , C12R1/55 , Y02P20/55 , Y10S435/886 , Y10S435/898
摘要： This invention relates to tricyclo compounds useful for treatment and prevention of resistance by transplanation, graft-versus-host diseases by medulla ossium transplanation, autoimmune diseases, infectious diseases, and the like, which can be represented by the formula: 1 to a process for their production, to a pharmaceutical composition containing the same and to a use thereof.
摘要翻译： 本发明涉及三环类化合物，其可用于治疗和预防耐药性，通过髓质移植，移植物抗宿主病，自身免疫性疾病，感染性疾病等，其可以由下式表示： 制备成含有该组合物的药物组合物及其用途。
-
公开(公告)号：US20040014745A1
公开(公告)日：2004-01-22
申请号：US10618743
申请日：2003-07-15
发明人： Akira Yamada , Satoshi Aoki
IPC分类号： A61K031/551 , A61K031/495 , A61K031/4164
CPC分类号： C07D213/75 , C07D211/58 , C07D295/26 , C07D401/12
摘要： This invention relates to new amide compounds having the potentiation of the cholinergic activity, etc., and represented by general formula nullInull. 1 wherein R1 is acyl, R2 is lower alkyl, etc., A is a single bond, 2 nullor nullSO2null, E is lower alkylene, etc, X is CH or N, Y is a single bond, etc., Q is nullCH2null, etc., and R3 and R4 are taken together to form lower alkylene, etc., and pharmaceutically acceptable salts thereof, to processes for preparation thereof and a pharmaceutical composition comprising the same.
摘要翻译： 本发明涉及具有增强胆碱能活性等的新型酰胺化合物，并且由通式[I]表示。 其中R 1为酰基，R 2为低级烷基等，A为单键或-SO 2 - ，E为低级亚烷基等，X为CH或N，Y为单键等 Q为-CH 2 - 等，R 3和R 4一起形成低级亚烷基等及其药学上可接受的盐，其制备方法和包含其的药物组合物 。
-
公开(公告)号：US20030235614A1
公开(公告)日：2003-12-25
申请号：US10412281
申请日：2003-04-14
发明人： Kazunari Yamashita , Eiji Hashimoto , Yukihiro Nomura , Fumio Shimojo , Shigeki Tamura , Takeo Hirose , Satoshi Ueda , Takashi Saitoh , Rinta Ibuki , Toshio Ideno
IPC分类号： A61K031/4745 , A61K031/407 , A61K009/22
CPC分类号： A61K31/453 , A61K9/141 , A61K9/143 , A61K9/145 , A61K9/146 , A61K9/1617 , A61K9/1623 , A61K9/1635 , A61K9/1641 , A61K9/1647 , A61K9/1652 , A61K9/4858 , A61K31/407 , A61K31/436
摘要： Providing an oral formulation of a macrolide compound where the dissolution of the macrolide compound is under sustained release; and a sustained-release formulation containing a composition in solid solution, where the macrolide compound is present at an amorphous state in a solid base.
摘要翻译： 提供大环内酯类化合物的口服制剂，其中大环内酯类化合物的溶解持续释放; 以及含有固体溶液组合物的缓释制剂，其中大环内酯类化合物在固体基质中以无定形状态存在。
-
公开(公告)号：US20030113912A1
公开(公告)日：2003-06-19
申请号：US10238738
申请日：2002-09-11
发明人： Yoshimasa Saito , Yoshiko Ueda , Kouichi Tamura , Yoko Takata , Hisashi Yamada , Tatsuo Yamashita , Masakazu Kobayashi
IPC分类号： A61K038/00 , A61K038/28 , C12N005/08
CPC分类号： A61K38/30 , A61K2300/00
摘要： This invention relates to a hematopoietic stem cell proliferating agent comprising IGF-I, a hematopoietic stem cell proliferating agent comprising IGF-I and at least one protein selected from among SCF, M-CSF, and G-CSF, and a method of growing hematopoietic stem cells which comprises culturing hematopoietic stem cells in a medium containing IGF-I and at least one protein selected from the group consisting of SCF and M-CSF. The hematopoietic stem cell proliferating agent of the invention causes hematopoietic stem cells to proliferate in the undifferentiated state whether in vivo or in vitro and can, therefore, be used for amelioration of the cytopenia induced by radiotherapy or chemotherapy using anticancer drugs, prevention of infectious diseases associated with lymphopenia, or in vitro culture for multiplication of hematopoietic stem cells and extrasomatic culture of recombinant stem cells in gene therapy.
摘要翻译： 本发明涉及造血干细胞增殖剂，其包含IGF-I，包含IGF-I的造血干细胞增殖剂和选自SCF，M-CSF和G-CSF中的至少一种蛋白质，以及造血造血干细胞增殖的方法 干细胞，其包括在含有IGF-I和至少一种选自SCF和M-CSF的蛋白质的培养基中培养造血干细胞。 本发明的造血干细胞增殖剂使造血干细胞在体内或体外以未分化状态增殖，因此可用于改善放射治疗或化学疗法诱导的使用抗癌药物，预防感染性疾病引起的血细胞减少 与淋巴细胞减少有关，或体外培养用于造血干细胞的繁殖和基因治疗中重组干细胞的外植体培养。
-
公开(公告)号：US20030068820A1
公开(公告)日：2003-04-10
申请号：US10198355
申请日：2002-07-19
发明人： Yoshimasa Saito , Yoshiko Ueda , Kouichi Tamura , Yoko Takata , Hisashi Yamada , Tatsuo Yamashita , Masakazu Kobayashi
IPC分类号： C12N005/08 , A61K038/18
CPC分类号： A61K38/30 , A61K2300/00
摘要： This invention relates to a hematopoietic stem cell proliferating agent comprising IGF-I, a hematopoietic stem cell proliferating agent comprising IGF-I and at least one protein selected from among SCF, M-CSF, and G-CSF, and a method of growing hematopoietic stem cells which comprises culturing hematopoietic stem cells in a medium containing IGF-I and at least one protein selected from the group consisting of SCF and M-CSF. The hematopoietic stem cell proliferating agent of the invention causes hematopoietic stem cells to proliferate in the undifferentiated state whether in vivo or in vitro and can, therefore, be used for amelioration of the cytopenia induced by radiotherapy or chemotherapy using anticancer drugs, prevention of infectious diseases associated with lymphopenia, or in vitro culture for multiplication of hematopoietic stem cells and extrasomatic culture of recombinant stem cells in gene therapy.
-
9.发明申请Anthranilic acid derivatives as inhibitors of the CGMP-phosphodiesterase 审中-公开邻氨基苯甲酸衍生物作为CGMP-磷酸二酯酶的抑制剂公开(公告)号：US20020193614A1
公开(公告)日：2002-12-19
申请号：US10050789
申请日：2002-01-18
发明人： Teruo Oku , Noriko Oku , Chikako Oku , Tomohito Oku , Kozo Sawada , Akio Kuroda , Takayuki Inoue , Natsuko Kayakiri , Yuki Sawada , Tsuyoshi Mizutani
IPC分类号： C07D307/02 , C07C271/26
CPC分类号： C07D213/40 , C07C227/30 , C07C227/32 , C07C2601/08 , C07C2601/14 , C07D207/14 , C07D207/48 , C07D211/58 , C07D231/12 , C07D233/56 , C07D235/14 , C07D249/08 , C07D307/22 , C07D317/58 , C07D333/20
摘要： Novel anthranilic acid derivatives having an inhibiting activity of cGMP-PDE are represented by the formula I where A is a lower alkylene group: 1 The anthranilic acid derivatives show pharmacological activity and may be used in pharmaceutical compositions as medications. The anthranilic acid derivatives can be formed by the reaction of a fluoro precursor with an amine. Pharmaceutical compositions containing the anthranilic acid derivatives can be used to treat or prevent human health disorders.
摘要翻译： 具有cGMP-PDE抑制活性的新型邻氨基苯甲酸衍生物由式I表示，其中A为低级亚烷基：邻氨基苯甲酸衍生物显示药理活性，可用作药物组合物作为药物。 邻氨基苯甲酸衍生物可以通过氟前体与胺的反应形成。 含有邻氨基苯甲酸衍生物的药物组合物可用于治疗或预防人类健康障碍。
-
公开(公告)号：US20020098162A1
公开(公告)日：2002-07-25
申请号：US09832841
申请日：2001-04-12
发明人： Ryuichi Morishita , Toshio Ogiwara , Toshiko Sugimoto , Kazuhiro Maeda , Ikuo Kawamura , Toshiyuki Chiba
IPC分类号： A61K038/19
CPC分类号： A61K31/00 , A61K38/00 , A61K48/005 , C12N15/113 , C12N2310/13 , C12N2310/315
摘要： Administration of a decoy, i.e. a compound which specifically antagonizes the nucleic acid domain to which NF-nullB is bound, is effective in the treatment and prevention of diseases caused by the transcriptional regulatory factor NF-nullB, such as ischemic diseases, inflammatory diseases, autoimmune diseases, cancer metastasis and invasion, and cachexia.
摘要翻译： 施用诱饵，即特异性拮抗NF-κB结合的核酸结构域的化合物在治疗和预防由转录调节因子NF-κB引起的疾病中是有效的，例如缺血性疾病，炎性疾病， 自身免疫性疾病，癌症转移和侵袭以及恶病质。
-
-
-
-
-
-
-
-
-
搜索结果
66 条记录 (耗时 0.028 秒)
